Related Experiment Video
Updated: Jul 7, 2025
05:43
Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
Published on: January 10, 2025
564
The Therapeutic Landscape in Chronic Cough
1Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester and Manchester Academic Health Science Centre, Wythenshawe Hospital, Southmoor Road, Manchester, M23 9LT, UK. jacky.smith@manchester.ac.uk.
Lung
|December 21, 2023
Summary
New antitussive therapies are emerging, with gefapixant recently licensed in Europe. This review covers existing unlicenced treatments and novel therapies in development for chronic cough conditions.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Therapeutics
Background:
- Chronic cough is a significant clinical challenge with limited effective treatments.
- The development of novel antitussive therapies has accelerated recently.
- Gefapixant represents the first new therapy licensed in Europe for chronic cough.
Purpose of the Study:
- To review current unlicenced treatments for chronic cough.
- To detail treatments in development for refractory chronic cough.
- To explore therapeutic options for cough associated with idiopathic pulmonary fibrosis and previously investigated compounds.
Main Methods:
- Literature review of antitussive therapies.
- Analysis of licensed and investigational drugs for chronic cough.
- Examination of compounds explored for cough treatment.
Main Results:
- Gefapixant is a newly licensed antitussive therapy in Europe.
- Various unlicenced treatments are currently used for chronic cough.
- Several novel compounds are under investigation for refractory chronic cough and idiopathic pulmonary fibrosis-related cough.
Conclusions:
- The landscape of chronic cough treatment is evolving with new therapeutic options.
- Further research and development are crucial for managing refractory chronic cough and related conditions.
- Investigational therapies show promise for patients with limited treatment alternatives.
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
3.9K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
3.9K
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
293
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
293
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K